2020
DOI: 10.1016/j.jaad.2020.04.153
|View full text |Cite
|
Sign up to set email alerts
|

Cyclosporine therapy during the COVID-19 pandemic

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
39
0
5

Year Published

2020
2020
2023
2023

Publication Types

Select...
10

Relationship

2
8

Authors

Journals

citations
Cited by 47 publications
(45 citation statements)
references
References 6 publications
1
39
0
5
Order By: Relevance
“…For cyclosporin A (CyA) as an approved therapeutic option for atopic dermatitis, in vitro studies have suggested antiviral effects [ 60 ]. T-cell-directed immunosuppression performed after organ transplantation (CyA, tacrolimus) is being discussed as a possible protective factor against serious clinical complications of SAS-CoV-2 infection [ 61 ], as well as the use of CyA in COVID-19 [ 62 , 63 ]. However, reliable clinical data have not yet been published.…”
Section: Recommendations For the Management Of Allergic/atopy-associamentioning
confidence: 99%
“…For cyclosporin A (CyA) as an approved therapeutic option for atopic dermatitis, in vitro studies have suggested antiviral effects [ 60 ]. T-cell-directed immunosuppression performed after organ transplantation (CyA, tacrolimus) is being discussed as a possible protective factor against serious clinical complications of SAS-CoV-2 infection [ 61 ], as well as the use of CyA in COVID-19 [ 62 , 63 ]. However, reliable clinical data have not yet been published.…”
Section: Recommendations For the Management Of Allergic/atopy-associamentioning
confidence: 99%
“…Für Cyclosporin A (CyA) als zugelassene Therapieoption für die atopische Dermatitis (AD) haben In-vitro-Untersuchungen antivirale Eigenschaften nahegelegt [60]. Eine nach Organtransplantation durchgeführte T-Zell-gerichtete Immunsuppression (CyA, Tacrolimus) wird als möglicher protektiver Faktor vor schweren klinischen Komplikationen einer SAS-CoV-2 Infektion diskutiert [61] und CyA für eine Anwendung bei Covid-19 diskutiert [62,63], belastbare klinische Daten sind bislang allerdings nicht publiziert. Zu beachten sind mögliche metabolische Interaktionen zwischen CyA und Lopinavir/Ritonavir (CYP3-Inhibitoren).…”
Section: Typ-2-blockade Bei Sars-cov-2unclassified
“…We highlight these dermatological drugs and review the adverse effects associated with other drugs being studied. [5][6][7][8]…”
Section: Introduction Imentioning
confidence: 99%